Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Theme survey for technologies that treat benign prostatic hyperplasia initiated by Swedish TLV

In February 2023, Swedish Medical Technologies Product (MTP) Council announced ongoing horizon scanning within the Orderly introduction framework. This framework has operated since 2020 and aims to manage the national introduction of novel technologies via a staged process: horizon scanning, selection of the method for evaluation, the decision on national collaboration, health economic evaluation, and recommendations by the MTP Council to regions about the introduction of the method and criteria for use.

As a horizon scanning stage, the Dental and Pharmaceutical Benefits Agency (TLV) is currently conducting a thematic survey regarding medical technologies to be used as an alternative to transurethral prostate resection in benign prostatic hyperplasia.

The application form is available on the TLV website and should be submitted no later than March 31, 2023.

See more information here and here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.